Don Casey, Key Advisor

Don Casey, a distinguished healthcare and pharmaceutical industry veteran, has joined Bonaventure Equity's Board of Advisors in a pivotal role as the company pioneers the way forward in cannabinoid and psychedelic medicine. Don brings over 40 years of diverse healthcare experience and strategic insight to BVE based on roles at Johnson and Johnson, Cardinal Health, Dentsply Sirona and multiple board roles.

Throughout his career, Don played a crucial role in identifying and supporting innovative startups and groundbreaking technologies in healthcare, accumulating deep knowledge of industry trends, regulatory landscapes, and investment strategies. His extensive background in venture capital, leadership roles, and unwavering commitment to improving human health align seamlessly with BVE's vision.

With a mission to bridge funding gaps in cannabinoid and psychedelic research, BVE invests in early-stage startups at the forefront of neuroscience and patient care, addressing diseases like Alzheimer's, fibromyalgia, PTSD, depression, stroke, and addiction. Don’s appointment to BVE's Board marks a momentous step forward as the company accelerates groundbreaking research and development efforts, unlocking the therapeutic potential of cannabinoids and psychedelics to treat a wide range of ailments, from mental health disorders to chronic pain management.